6.455
price up icon0.86%   0.085
 
loading
Schlusskurs vom Vortag:
$6.37
Offen:
$6.35
24-Stunden-Volumen:
1.04M
Relative Volume:
1.36
Marktkapitalisierung:
$488.44M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-2.8689
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+0.08%
1M Leistung:
+36.99%
6M Leistung:
+9.45%
1J Leistung:
+430.99%
1-Tages-Spanne:
Value
$6.20
$6.50
1-Wochen-Bereich:
Value
$5.875
$6.50
52-Wochen-Spanne:
Value
$1.135
$7.20

Personalis Inc Stock (PSNL) Company Profile

Name
Firmenname
Personalis Inc
Name
Telefon
650-752-1300
Name
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Name
Mitarbeiter
229
Name
Twitter
@PersonalisInc
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
PSNL's Discussions on Twitter

Vergleichen Sie PSNL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
PSNL
Personalis Inc
6.4555 488.44M 73.48M -108.30M -67.17M -2.25
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
408.12 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
197.96 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
529.77 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
118.64 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
156.45 27.64B 15.50B 1.33B 2.16B 7.34

Personalis Inc Stock (PSNL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-15 Eingeleitet Guggenheim Buy
2025-03-17 Eingeleitet Craig Hallum Buy
2023-02-06 Hochstufung Needham Hold → Buy
2022-01-07 Hochstufung BofA Securities Neutral → Buy
2021-11-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-11-03 Herabstufung Needham Buy → Hold
2021-10-15 Fortgesetzt Cowen Outperform
2021-09-20 Bestätigt Needham Buy
2021-05-06 Hochstufung Oppenheimer Perform → Outperform
2021-01-28 Eingeleitet Truist Buy
2021-01-04 Herabstufung BofA Securities Buy → Neutral
2020-11-12 Bestätigt Needham Buy
2020-11-06 Herabstufung Oppenheimer Outperform → Perform
2020-10-19 Eingeleitet Citigroup Buy
2020-10-08 Eingeleitet BTIG Research Buy
2020-08-27 Eingeleitet H.C. Wainwright Buy
2020-08-18 Eingeleitet Needham Buy
2019-09-26 Hochstufung BofA/Merrill Neutral → Buy
2019-07-15 Eingeleitet BofA/Merrill Neutral
2019-07-15 Eingeleitet Cowen Outperform
2019-07-15 Eingeleitet Morgan Stanley Overweight
2019-07-15 Eingeleitet Oppenheimer Outperform
Alle ansehen

Personalis Inc Aktie (PSNL) Neueste Nachrichten

pulisher
Jun 18, 2025

The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394% - Yahoo

Jun 18, 2025
pulisher
Jun 17, 2025

Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 09, 2025

Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha

Jun 08, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Grows Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Personalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LP - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Ameriprise Financial Inc. Has $199,000 Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Sells 30,474 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - BioSpace

Jun 04, 2025
pulisher
Jun 04, 2025

Personalis reveals ctDNA test predicts cervical cancer relapse By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Personalis reveals ctDNA test predicts cervical cancer relapse - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Personalis (PSNL) Blood Test Shows Promise in Detecting Cervical Cancer Early | PSNL Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Personalis (PSNL) Showcases Promising Results for NeXT Personal in Breast Cancer Care | PSNL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Yahoo Finance

Jun 02, 2025
pulisher
Jun 01, 2025

Northern Trust Corp Lowers Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World

Jun 01, 2025
pulisher
May 27, 2025

Millennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 27, 2025
pulisher
May 26, 2025

BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 26, 2025
pulisher
May 22, 2025

Personalis and Academic Partners to Present Latest Data on Ultra - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

New Clinical Data Reveals Groundbreaking Early Cancer Detection ResultsPersonalis ASCO Preview - Stock Titan

May 22, 2025
pulisher
May 19, 2025

Personalis Holds Virtual Annual Stockholders Meeting - TipRanks

May 19, 2025
pulisher
May 19, 2025

PSNL to Discuss Future Plans in Upcoming Virtual Meeting | PSNL Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $8.00 - Defense World

May 18, 2025
pulisher
May 17, 2025

Personalis Inc (PSNL): A Sitting Duck With -162.63% Upside Potential - Stocksregister

May 17, 2025
pulisher
May 17, 2025

Guggenheim Begins Coverage on Personalis (NASDAQ:PSNL) - Defense World

May 17, 2025
pulisher
May 16, 2025

Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC - Defense World

May 16, 2025
pulisher
May 16, 2025

Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter

May 16, 2025
pulisher
May 16, 2025

Personalis, Inc. (NASDAQ:PSNL) Shares Acquired by Stifel Financial Corp - Defense World

May 16, 2025
pulisher
May 15, 2025

Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Ta - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’ - TipRanks

May 15, 2025
pulisher
May 15, 2025

Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Target | PSNL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Guggenheim Initiates Personalis at Buy With $6 Price Target - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating | PSNL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 15, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Takes Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 15, 2025
pulisher
May 14, 2025

Leading Genomics Company Personalis Takes Center Stage at Major Craig-Hallum Investor Conference - Stock Titan

May 14, 2025
pulisher
May 12, 2025

Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

What is HC Wainwright’s Estimate for Personalis Q2 Earnings? - Defense World

May 12, 2025
pulisher
May 10, 2025

Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN

May 10, 2025
pulisher
May 09, 2025

HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter

May 08, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World

May 08, 2025
pulisher
May 07, 2025

Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia

May 07, 2025
pulisher
May 07, 2025

Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks

May 07, 2025
pulisher
May 07, 2025

Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq

May 07, 2025

Finanzdaten der Personalis Inc-Aktie (PSNL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Personalis Inc-Aktie (PSNL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Moore Stephen Michael
SVP and Chief Legal Officer
May 16 '25
Sale
4.95
1,675
8,291
64,200
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
May 16 '25
Sale
4.95
910
4,504
124,957
Tachibana Aaron
CFO AND COO
Jan 28 '25
Sale
5.79
708
4,099
166,390
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
Jan 28 '25
Sale
5.79
519
3,005
123,367
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
Dec 16 '24
Sale
3.82
4,834
18,466
123,886
Moore Stephen Michael
SVP and Chief Legal Officer
Dec 16 '24
Sale
3.82
1,513
5,780
65,875
Tachibana Aaron
CFO AND COO
Dec 16 '24
Sale
3.82
6,865
26,224
167,098
Tachibana Aaron
CFO AND COO
Nov 18 '24
Sale
3.79
1,307
4,954
173,963
Moore Stephen Michael
SVP and Chief Legal Officer
Nov 18 '24
Sale
3.79
1,693
6,416
67,388
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
Nov 18 '24
Sale
3.79
921
3,491
128,720
diagnostics_research DGX
$176.92
price down icon 0.01%
diagnostics_research WAT
$354.24
price up icon 0.53%
diagnostics_research LH
$256.86
price down icon 0.30%
$166.98
price down icon 0.23%
diagnostics_research MTD
$1,180.33
price down icon 1.06%
diagnostics_research IQV
$156.74
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):